Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to fight tough pancreatic cancer

NCT ID NCT05304936

First seen Dec 17, 2025 · Last updated Apr 29, 2026 · Updated 16 times

Summary

This early-phase trial tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to help the immune system attack the cancer while blocking a protein that helps tumors grow. The main goals were to check safety and find the best dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • HonorHealth

    Scottsdale, Arizona, 85258, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • National Institute of Health/ National Cancer Institute

    Bethesda, Maryland, 20892, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.